We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




DNA Test Launched for Laser Eye Surgery Safety

By LabMedica International staff writers
Posted on 27 May 2014
Print article
Image: Granular corneal dystrophy (Photo courtesy of Dr. B.H. Feldman).
Image: Granular corneal dystrophy (Photo courtesy of Dr. B.H. Feldman).
A genetic test has been introduced that can detect both Avellino Corneal Dystrophy (ACD) and another genetic mutation, Granular Corneal Dystrophy type I (GCD1).

A patient with GCD1 who undergoes vision correction surgery, such as Laser-Assisted in situ Keratomileusis (LASIK), Laser-Assisted Sub-Epithelial Keratectomy (LASEK) or Photorefractive keratectomy (PRK) are at extreme risk of experiencing eventual blindness.

The Avellino DNA Dual Test (Avellino Laboratory; Menlo Park, CA, USA) is able to detect the presence of the genetic mutation, allowing the patient to take precautionary steps to postpone the progression of the condition, including avoiding vision correction surgery. The Avellino DNA Dual Test is easy and safe. The test involves a simple mouth swab to determine whether a person carries the GCD1 or the GCD2 (ACD) gene mutation. Specifically, the ophthalmologist takes 10 swipes from the inside of each cheek in order to obtain an adequate sample. The sample is then sent to Avellino Lab USA, a Clinical Laboratory Improvement Amendments (CLIA) certified molecular diagnostic testing laboratory. Within 24 to 48 hours, the results are provided to the physician to share with the patient. Avellino Laboratory has branches in North America, Western Europe, and Asia.

Granular Corneal Dystrophy (type 1 and 2) has been diagnosed in patients throughout the world and is one of the more well-known corneal dystrophies related to genetic mutations. Unfortunately, many physicians assume incorrectly that they can diagnose the condition through a visual examination and family history. However, many patients do not show physical symptoms of the condition until later in life. Consequently, relying solely on traditional methods for diagnosis can put patients at risk.

Tom Tooma, MD, founder of NVISION Laser Eye Center, said, (Newport Beach, CA, USA) said, “We have been utilizing the Avellino DNA Test for LASIK Safety since its availability in the United States, and it has been a fantastic tool for both our physicians and patients in increasing their confidence prior to LASIK. Now, with the Avellino DNA Dual Test, patients can go into treatment knowing they are even more protected from adverse outcomes such as loss of vision.” The Avellino DNA Test for LASIK Safety has become the standard of care in Korea with 160 LASIK clinics using this test and in Japan more than 80% of LASIK patients were tested.

Related Links:

Avellino Laboratory
NVISION Laser Eye Center 


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Procalcitonin Rapid Test
StrongStep Procalcitonin Test
New
Multi-Purpose Centrifuge
GCC-MP

Print article

Channels

Immunology

view channel
Image: Example image of the high-throughput microscopy method used in the study, showing immune cells stained with different fluorescence markers (Photo courtesy of Felix Kartnig/CeMM, MedUni Vienna)

Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies

Rheumatoid arthritis is the most common inflammatory joint disorder, with women three times as likely to suffer from the condition as men. Treatment advances made over the past decades have led to the... Read more

Microbiology

view channel
Image: RNA sequencing directly from whole blood aims to expand access to LRTI testing (Photo courtesy of CARB-X)

Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood

Pneumonia and lower-respiratory-tract infections (LRTIs) are among the top causes of illness and death globally, particularly in vulnerable populations such as the elderly, young children, and immunocompromised... Read more

Pathology

view channel
Image: Lunit SCOPE HER2 is an AI-powered solution designed to detect HER2 expression profile (Photo courtesy of Lunit)

AI-Powered Pathology Solutions Accurately Predict Outcomes for HER2-Targeted Therapy in Metastatic CRC

A new study has highlighted how artificial intelligence (AI)-powered analysis of HER2 and the tumor microenvironment (TME) can improve patient stratification and predict clinical outcomes more effectively.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.